{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:52:10Z","timestamp":1792788730469,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.ajo.2013.12.018","type":"journal-article","created":{"date-parts":[[2014,1,2]],"date-time":"2014-01-02T22:37:12Z","timestamp":1388702232000},"page":"825-833.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Clinical Utilization of Anti-VEGF Agents and Disease Monitoring in Neovascular Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"157","author":[{"given":"Nancy M.","family":"Holekamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Shi","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szil\u00e1rd","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arghavan","family":"Almony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ajo.2013.12.018_bib1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"The Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States","volume":"122","author":"Congdon","year":"2004","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2013.12.018_bib2","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/archopht.118.6.819","article-title":"Causes of blindness and visual impairment in a population of older Americans: The Salisbury Eye Evaluation Study","volume":"118","author":"Mu\u00f1oz","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2013.12.018_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/bjo.81.2.154","article-title":"Increased expression of angiogenic growth factors in age-related maculopathy","volume":"81","author":"Kliffen","year":"1997","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2013.12.018_bib4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ajo.2013.12.018_bib5","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3109\/02713683.2011.647227","article-title":"Evaluation of changes in choroidal neovascularization secondary to age-related macular degeneration after anti-VEGF therapy using spectral domain optical coherence tomography","volume":"37","author":"You","year":"2012","journal-title":"Curr Eye Res"},{"issue":"3","key":"10.1016\/j.ajo.2013.12.018_bib6","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/ICU.0b013e328352411c","article-title":"Preferred therapies for neovascular age-related macular degeneration","volume":"23","author":"Lally","year":"2012","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.ajo.2013.12.018_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005139.pub2","article-title":"Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration","volume":"2","author":"Vedula","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.ajo.2013.12.018_bib8","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/bjo.2007.118562","article-title":"Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review","volume":"91","author":"Takeda","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"16","key":"10.1016\/j.ajo.2013.12.018_bib9","doi-asserted-by":"crossref","DOI":"10.3310\/hta12160","article-title":"Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation","volume":"12","author":"Colquitt","year":"2008","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.ajo.2013.12.018_bib10","doi-asserted-by":"crossref","first-page":"c2459","DOI":"10.1136\/bmj.c2459","article-title":"Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study","volume":"340","author":"Tufail","year":"2010","journal-title":"BMJ"},{"issue":"20","key":"10.1016\/j.ajo.2013.12.018_bib11","first-page":"1897","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"363","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ajo.2013.12.018_bib12","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2013.12.018_bib13","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"Chakravarthy","year":"2012","journal-title":"Ophthalmology"},{"issue":"14","key":"10.1016\/j.ajo.2013.12.018_bib14","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ajo.2013.12.018_bib15","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ajo.2013.12.018_bib16","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","article-title":"An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration","volume":"143","author":"Fung","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2013.12.018_bib17","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ophtha.2010.09.004","article-title":"Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study","volume":"118","author":"Schmidt-Erfurth","year":"2011","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ajo.2013.12.018_bib18","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.ophtha.2009.05.024","article-title":"A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration","volume":"116","author":"Boyer","year":"2009","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2013.12.018_bib19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1","volume":"145","author":"Regillo","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"9900","key":"10.1016\/j.ajo.2013.12.018_bib20","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularization: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ajo.2013.12.018_bib21","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","article-title":"Twelve-month efficacy and safety of 0.5\u00a0mg or 2.0\u00a0mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"120","author":"Busbee","year":"2013","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2013.12.018_bib22","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ophtha.2009.07.023","article-title":"Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study","volume":"117","author":"Fong","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2013.12.018_bib23","unstructured":"Hansen LG, Chang S. Health research data for the real world: the MarketScan databases. Available at http:\/\/www.truvenhealth.com\/assets\/2012_Truven_MarketScan_white_paper.pdf. Accessed September 25, 2013."},{"key":"10.1016\/j.ajo.2013.12.018_bib24","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2147\/OPTH.S14684","article-title":"Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration","volume":"4","author":"Rotsos","year":"2010","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2013.12.018_bib25","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3129\/i10-082","article-title":"Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective review","volume":"45","author":"Bandukwala","year":"2010","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.ajo.2013.12.018_bib26","unstructured":"American Society of Retina Specialists (ASRS). Annual preferences and trends survey, 2011. Available (with membership) at http:\/\/www.asrs.org\/asrs-community\/pat-survey. Accessed September 25, 2013."},{"key":"10.1016\/j.ajo.2013.12.018_bib27","unstructured":"American Society of Retina Specialists (ASRS). Annual preferences and trends survey, 2012. Available (with membership) at http:\/\/www.asrs.org\/asrs-community\/pat-survey. Accessed September 25, 2013."},{"issue":"5","key":"10.1016\/j.ajo.2013.12.018_bib28","first-page":"146","article-title":"Intravitreal anti-VEGF therapy for neovascular age-related macular degeneration and the risk of stroke","volume":"104","author":"Cleary","year":"2011","journal-title":"Ir Med J"},{"issue":"2","key":"10.1016\/j.ajo.2013.12.018_bib29","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ajo.2011.01.053","article-title":"Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration","volume":"152","author":"Day","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2013.12.018_bib30","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1517\/14712598.2012.707176","article-title":"Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration","volume":"12","author":"Costagliola","year":"2012","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"10.1016\/j.ajo.2013.12.018_bib31","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1185\/03007995.2011.585394","article-title":"A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab","volume":"27","author":"Mitchell","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"10.1016\/j.ajo.2013.12.018_bib32","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.ophtha.2011.12.016","article-title":"HORIZON: An open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration","volume":"119","author":"Singer","year":"2012","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2013.12.018_bib33","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1136\/bjo.2008.149674","article-title":"Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements","volume":"93","author":"Shah","year":"2009","journal-title":"Br J Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939413008088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939413008088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:10:04Z","timestamp":1757596204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939413008088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0002939413008088"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2013.12.018","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Utilization of Anti-VEGF Agents and Disease Monitoring in Neovascular Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2013.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}